INCYNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
INCYTE CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$113.25+0.18 (+0.16%)
Close on Oct 19, 2026
- Market cap
- $23.58B
- P/E (TTM)
- 14.4
- Dividend yield
- –
INCYTE CORP revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | $1.49B | $1.10B | $1.22B | $1.15B | $1.06B | $922.27M | $1.02B | $962.99M | $906.57M | $729.92M | $861.73M | $783.20M | 88.9% | +40.5% |
| JAKAFI | $816.66M | $757.76M | $828.24M | $791.07M | $763.79M | $709.41M | $773.11M | $741.18M | $705.97M | $571.84M | $695.13M | $636.25M | 48.8% | +6.9% |
| OPZELURA | $449.74M | $143.02M | $207.28M | $187.97M | $164.50M | $118.71M | $161.60M | $139.27M | $121.70M | $85.72M | – | – | 26.9% | +173.4% |
| Product royalty revenues | $174.69M | $151.19M | $184.05M | $171.12M | $151.12M | $130.62M | $159.29M | $156.88M | $137.19M | $125.97M | $149.61M | $130.83M | 10.4% | +15.6% |
| JAKAVI | $124.19M | $105.56M | $130.23M | $125.65M | $109.71M | $92.15M | $114.19M | $115.74M | $99.32M | $89.60M | – | – | 7.4% | +13.2% |
| NIKTIMVO | $60.31M | $55.09M | $56.04M | $45.83M | $36.15M | $13.61M | $0 | $0 | $0 | $0 | – | – | 3.6% | +66.8% |
| MINJUVI/MONJUVI | $53.69M | $49.23M | $41.91M | $41.99M | $31.13M | $29.55M | $32.81M | $31.44M | $31.12M | $23.87M | $8.99M | $8.35M | 3.2% | +72.5% |
| ZYNYZ | $49.95M | $41.39M | $31.75M | $22.67M | $8.92M | $3.01M | $1.37M | $694.00K | $651.00K | $467.00K | $582.00K | $98.00K | 3.0% | +459.9% |
| OLUMIANT | $38.48M | $36.41M | – | $37.11M | $33.48M | $30.80M | – | $34.80M | $31.70M | $30.59M | – | – | 2.3% | +14.9% |
| ICLUSIG | $34.39M | $35.46M | $34.22M | $37.58M | $32.73M | $29.54M | $27.37M | $29.75M | $26.86M | $30.34M | $27.13M | $27.72M | 2.1% | +5.1% |
| PEMAZYRE | $23.42M | $22.54M | – | $22.74M | $22.19M | $18.44M | – | $20.66M | $20.27M | $17.68M | – | – | 1.4% | +5.5% |
| Milestone and contract revenues | $11.20M | $17.00M | $100.00M | $45.00M | $5.00M | $0 | $0 | $18.00M | $0 | $25.00M | $2.00M | $5.00M | 0.7% | +124.0% |
| TABRECTA | $6.69M | $5.98M | $7.14M | $6.51M | $6.63M | $6.41M | $6.29M | $5.93M | $5.30M | $5.23M | – | – | 0.4% | +0.9% |
| Other | $5.33M | $3.25M | $3.47M | $1.86M | $1.29M | $1.27M | $333.00K | $414.00K | $876.00K | $548.00K | – | – | 0.3% | +314.1% |
| Milestone and contract revenues | – | – | – | – | – | – | – | – | – | – | – | $5.00M | – | – |
| OLUMIANT Royalty Revenues | – | – | – | – | – | – | $38.49M | $34.80M | $31.70M | $30.59M | $40.36M | $29.62M | – | – |
| Milestone and contract revenues | – | – | – | – | – | – | – | $18.00M | $0 | $25.00M | – | $5.00M | – | – |
| JAKAVI Royalty Revenues | – | – | – | – | – | – | – | $115.74M | $99.32M | $89.60M | – | $96.55M | – | – |
| PEMAZYRE | – | – | – | – | – | – | $23.14M | $20.66M | $20.27M | $17.68M | $20.65M | $18.94M | – | – |
| TABRECTA Royalty Revenues | – | – | – | – | – | – | – | $5.93M | $5.30M | $5.23M | – | $4.14M | – | – |
| MINJUVI | – | – | – | – | – | – | – | – | – | – | $8.99M | $8.35M | – | – |
| OPZELURA | – | – | – | – | – | – | – | $139.27M | $121.70M | $85.72M | – | $91.84M | – | – |
| PEMAZYRE Royalty Revenues | – | – | – | – | – | – | $333.00K | $414.00K | $876.00K | $548.00K | $683.00K | $523.00K | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.56B | $1.17B | $1.42B | $1.26B | $1.13B | $981.56M | $1.09B | $1.07B | $989.03M | $828.20M | – | – | 93.2% | +37.8% |
| Europe | $105.13M | $92.43M | $75.99M | $100.31M | $78.83M | $68.61M | $88.86M | $66.46M | $53.59M | $51.50M | – | – | 6.3% | +33.4% |
| Other countries | $8.80M | $8.78M | $6.08M | $4.41M | $4.35M | $2.73M | $2.51M | $1.37M | $1.14M | $1.20M | – | – | 0.5% | +102.3% |
From the segment and revenue-disaggregation notes of Incyte's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.